COMMUNIQUÉS West-GlobeNewswire

miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum

20/12/2018 - 13:00

BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced [...]

Form 8 (DD) - Steven Gillis

20/12/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Form 8 (DD) - Sara Mathew

20/12/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

New Data on AlloSure Confirms Its Clinical Utility in Repeat Kidney Transplant Recipients

20/12/2018 - 13:00

Study published in the American Journal of Transplantation BRISBANE, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development [...]

iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures

20/12/2018 - 13:00

Added Funds to support global commercialization of cancer detection capability and cancer therapy technology NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology company [...]

Form 8 (DD) - Albert Stroucken

20/12/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Form 8 (DD) - Susan Kilsby

20/12/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Form 8 (DD) - David Ginsburg

20/12/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Avivagen Announces Proposed Extension of Warrants

20/12/2018 - 12:30

OTTAWA, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, today announced that it will be [...]

Eton Pharmaceuticals Reports Third Quarter Results and Business Update

20/12/2018 - 12:30

Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical [...]

ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions

20/12/2018 - 12:08

Call Scheduled for 9am Eastern Time RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and [...]

Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™

20/12/2018 - 12:00

PEDMARK TM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. RESEARCH TRIANGLE PARK [...]

Genmab Announces European Commission Approval of DARZALEX® (daratumumab) Split Dosing Regimen

20/12/2018 - 11:26

Media Release Split dosing regimen approved by European Commission Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days Approval supported by data from EQUULEUS ( [...]

Herb Names Maverick Technology Solutions’ ROSINBOMB™ Rocket the Best Portable Rosin Press

20/12/2018 - 11:00

The “Voice of Cannabis Culture” Names the Rocket the Best Press to Take Anywhere and Everywhere RENO, Nev., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Maverick Technology Solutions (OTC:MVRK) innovator and manufacturer of the [...]

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

20/12/2018 - 08:45

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a [...]

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

20/12/2018 - 08:32

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a [...]

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

20/12/2018 - 08:28

– Global SAVANNAH study of savolitinib / Tagrisso ® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among the most frequent mechanisms of acquired resistance t o [...]

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

20/12/2018 - 08:00

– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all development costs of [...]

Rule 2.9 Announcement

20/12/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 December 2018 [...]